| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 67028 |
Intravitreal injection of a pharmacologic agent |
2,217 |
1,740 |
$340K |
| 92012 |
Ophthalmological services: medical examination and evaluation, intermediate, established patient |
4,006 |
2,972 |
$265K |
| 92014 |
Ophthalmological services: medical examination and evaluation, comprehensive, established patient |
1,280 |
1,005 |
$195K |
| 92134 |
|
4,277 |
3,204 |
$137K |
| 76512 |
|
1,105 |
566 |
$113K |
| 92202 |
|
2,666 |
2,157 |
$75K |
| C9257 |
Injection, bevacizumab, 0.25 mg |
2,183 |
1,146 |
$71K |
| 92250 |
|
980 |
787 |
$64K |
| 92004 |
Ophthalmological services: medical examination and evaluation, comprehensive, new patient |
129 |
117 |
$54K |
| 92100 |
|
598 |
359 |
$20K |
| J9035 |
Injection, bevacizumab, 10 mg |
53 |
35 |
$7K |
| 92002 |
|
100 |
70 |
$6K |
| 92019 |
|
14 |
13 |
$591.07 |
| J3300 |
Injection, triamcinolone acetonide, preservative free, 1 mg |
99 |
56 |
$342.22 |
| 92015 |
Determination of refractive state |
19 |
12 |
$186.30 |
| G9903 |
Patient screened for tobacco use and identified as a tobacco non-user |
770 |
589 |
$0.00 |
| 1036F |
|
887 |
668 |
$0.00 |
| 4177F |
|
17 |
13 |
$0.00 |
| G8397 |
Dilated macular or fundus exam performed, including documentation of the presence or absence of macular edema and level of severity of retinopathy |
98 |
79 |
$0.00 |
| J3490 |
Unclassified drugs |
186 |
114 |
$0.00 |
| 5010F |
|
98 |
79 |
$0.00 |
| 4040F |
|
582 |
449 |
$0.00 |
| 2024F |
|
253 |
201 |
$0.00 |
| G9744 |
Patient not eligible due to active diagnosis of hypertension |
573 |
422 |
$0.00 |
| 2021F |
|
98 |
79 |
$0.00 |
| 2022F |
|
253 |
201 |
$0.00 |
| 2026F |
|
253 |
201 |
$0.00 |
| G8427 |
Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications |
871 |
655 |
$0.00 |
| 0517F |
|
69 |
65 |
$0.00 |